La relación entre el asma y la enfermedad pulmonar obstructiva crónica
DOI:
https://doi.org/10.51481/amc.v49i1.288Palabras clave:
Asma, EPOC, bronquitis crónica, enfisema pulmonar, Teoría Holandesa , obstrucción de la vía aérea, remodelamiento de la vía aéreaResumen
Asma y enfermedad pulmonar obstructiva crónica (EPOC) son enfermedades pulmonares comunes con semejanzas y diferencias. Estudios genéticos recientes han dado información importante acerca de los múltiples loci susceptibles para cada enfermedad. Estudios del genoma han mostrado resultados similares en al menos una región cromosomal en ambas enfermedades, así como también evidencia de la interacción con factores ambientales (por ejemplo, el fumado activo en los pacientes con EPOC, o el pasivo en aquellos con asma). Existen pocos estudios recientes acerca del remodelamiento de la vía aérea y su importancia en pacientes asmáticos persistentes crónicos, lo que podría explicar de cierta forma la progresión de estas personas a enfermedades pulmonares obstructivas crónicas.
Descargas
Citas
Postma D, Boezen M. Rationale for Dutch Hypothesis – allergy and Airway hiperresponsiveness as Genetic Factors and their interaction with environment in the development of asthma and COPD. Chest 2004; 126: 96S-104S.
Smith O, Helms J. Genetic/environmental determinants of adult chronic obstructive pulmonary disease and possible links with childhood wheezing. Ped Resp Rev 2001; 2: 178-183
Jenkins C, Thompson P, Gibson P, Wood-Baker R. Distinguishing asthma and chronic obstructive pulmonary disease: why, why not and how? Med J Aust 2005; 183: 35S-37S.
Bleecker E. Similarities and differences in asthma and COPD- The Dutch Hypothesis. Chest 2004;126 : 93S-95S.
Meyers D, Larj M, Lange L. Genetics of asthma and COPD. Similar resultants for different phenotypes. Chest 2004; 126:105S-110S.
Adcock I, Ford P, Ito K, Barnes P. Epigenetic and airways disease. Respir Res 2006; 7: 21.
Sandforf A, Weir T. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 77S-121S.
Siafakas N, Vermeire P, Pride N, Backer V. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. Eur Resp J 1995; 8 : 13981420.
World Health Organization. The GOLD global strategy for the management and prevention of COPD. Am J Respir Crit Care Med 2001; 163:1256-1276.
Silverman M, Wilson N. Asthma- time for change of name. Arch Dis Child 1997; 77: 62-64.
Mannino DM, Gagnon RC, Petty TL. Obstructive lung disease and low function in adults in the United States; data from the national health and nutrition examination survey, 1988-1994. Arch Intern Med 2000; 160:1683-1689.
Goeman D y Douglass J. Understanding asthma in older Australians: a qualitative approach. Med J Aust 2005; 183:26S-27S.
Anderson G, Morrison J. Molecular biology and genetics of allergy and asthma. Arch Dis Child 1998; 78:488-496.
Borg B, Reid D, Walters E, Johns D. Bronchodilator reversibility testing: laboratory practices in Australia and New Zealand. Med J Aust 2004; 180: 610-613.
Iniciativa global para manejo y prevención del asma: GINA.2004. Disponible en: http://www.ginasthma.org.
Silva G., Sherrill D, Guerra S, Barbee R. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65
Silverman E, Speizer F . Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80:501522.
Meyer P, Mannino D, Redd S. Characteristics of adults dying with chronic obstructive pulmonary disease. Chest 2002; 122:2003-2008.
Organización Mundial de la Salud. Word. Health Report. Ginebra, Suiza. 2000. Disponible en: http://www.who.int/whr/2000/en/ statistics.htm.
Mannino D. Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity Chest 2002;121;121S-126S
Xu X, Rijcken B, Schouten J, Weiss S. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 1997; 350: 1431-1434.
Yates M. How is the diagnosis of asthma in older people established in clinical practice? Med J Aust 2005; 183: S44-S46.
Abramson M. Respiratory symptoms and lung function in older people with asthma or chronic obstructive pulmonary disease. Med. J Austr 2005; 183:S23-S25.
Sandforf A, Chagani T, Weir T, Connett J, Anthonisen N, Paré P.
Susceptibility genes for rapide decline of lung function in the lung health study. Am J Respir Crit Care Med 2001; 163:469-473.
Tobin M. Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2002.Am J Respir Crit Care Med 2003; 167:356-370.
Palmer J. Functional Genomics of Lung disease. Am. J. Resp. Cell and Molecular Biology. 2004; 31: 13S-17S
Hofhuis W, Jongste J. Merkus P Adverse health effects of prenatal and Postnatal tobacco smoke exposure on children. Arch Dis Chile 2003;88:1086-1090
Ulrick CS, Backer V. Nonreversible airfl ow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999; 14:892-896.
Sciurba F. Physiologic Similarities and Differences between COPD and Asthma. Chest 2004; 126:117S-124S)
Grootendorst D, Rabe, K. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1:77-87.
Lewis S, Pavord I, Stringer J, Knox A, Weiss S, Britton J. The Relation Between Peripheral Blood Leukocyte Count and Respiratory Symptoms, Atopy, Lung Function, and Airways Responsiveness in Adults. Chest 2001;119:105-114.
Marc M, Korosec P, Kosnik M, Kern I, Flezar M, Suskovic S. Complement factors C3a, C4a, C5a, in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol. 2004; 31: 216-219.
Keatings V, Collins P, Scott D, Barnes P. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum form patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153: 530-4
Basyigit I, Yildiz F, Yildirim E, Boyaci H. Ilgazli A. Body mass index and serum and sputum TNF-alpha levels relation in asthma and COPD. J Tuberc Thorax Tuberk Toraks 2004. 52: 256-61.
Donohue J. Therapeutic Responses in Asthma and COPD. Chest 2004; 126;125S-137S.
Selroos O, Pietinalho A, Lofroos A, Riska H. Effect of early vs. late intervention with inhaled corticosteroids in asthma. Chest 1995; 108:1228-34.
Hudon C, Turcotte H, Laviolette M, Carier G, Boulet L. Characteristics of bronchial asthma with incomplete reversibility or airfl ow obstruction Ann Alergy Asthma Immunol 1997; 78:1956-202.
Vonk J, Jongepier H, Panhuysen C, Schouten J. Bleecker E, Postma D. Risk factors associated with the presence irreversible airfl ow limitation and reduced transfer coeffi cient in patients with asthma after 26 years of follow up. Thorax 2003; 58:322-327.
Xuan W, Marks G, Toelle B, Belousova E, Peat J, Berry G. Risk factors for onset and remission of atopy, wheeze, and airway hiperresponsiveness. Thorax 2002; 57:104-109.
Elias J. The relationship between asthma and COPD. Chest 2004; 126: 111S-116S.
Bunbacea D, Campbell D, Nguyen L, Carr D, Barnes P, Robinson D. Parameters associates with persistent airfl ows obstruction severe asthma. Eur Respir J 2004; 204: 122-128.
Gaga M. Fixed obstruction in severe asthma: not just a matter of time. Eur Respir J 2004; 234:8-10.
Backman K, Greenberger P, Patterson R. Airways obstruction in patients with long-term asthma consistence with “irreversible asthma”. Chest 1977; 122:1234-1240.
Molfi no N., Genetics of COPD, Chest 2004; 125:1929-1940
Lomas D. Silverman E. The genetics of chronic obstructive pulmonary disease. Respir Res 2001; 2:20-26.
Hersh C, DeMeo D, Lazarus R, Celedón J, Raby B, Benditt J. Genetic Association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 977-984
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2008 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
